FDA warned Korea Filler Experts that its website sells unapproved and misbranded injectable botulinum toxin drugs, including Nabota 100UI, to U.S. consumers.
What happened
FDA reviewed www.koreafillerexperts.com and found it offering injectable botulinum toxin drug products for sale to U.S. consumers, including “Nabota 100UI” with claims such as “Blepharospasm elimination” and “Hyperhidrosis elimination.” FDA said the products are unapproved new drugs and misbranded because their labeling lacks adequate directions for use. There was no inspection.
What FDA found
The website offers “Nabota 100UI,” an injectable botulinum toxin type A product, for sale in the U.S. without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The product is a prescription drug intended for conditions a layperson cannot safely self-diagnose or treat, and its labeling lacks adequate directions for use, so it is misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Because the drug is not approved in the U.S., it is not exempt from the adequate-directions requirement.
21 CFR 201.115(a)Offering the drug for sale to U.S. consumers causes misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days describing corrective steps and how it will prevent recurrence, or explain why it believes the products are not violations.
Who should pay attention
- U.S. consumers who buy injectables online
- med spas and clinics considering imported botulinum toxin
- online sellers of foreign drug products
This is a summary. Read the original letter on fda.gov.